In a new deal with Alloy Therapeutics, Biogen—the makers of Leqembi—is investing in RNA technology that could point toward what comes next in Alzheimer’s care.
Could Leqembi be given faster and more easily in the future? The new Biogen–Alteogen deal suggests it’s possible—but it doesn’t confirm changes to Leqembi. Here’s what professionals and families should understand.
The diagnostic and treatment network behind Leqembi may be its biggest competitive edge.
Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to five years after an Alzheimer’s diagnosis. One medication significantly reduced the risk of developing severe dementia.
New research reveals that Leqembi’s Fc region switches on microglia — the brain’s immune cells — helping them clear toxic amyloid. Here’s why that mechanism matters for treatment and safety.
A safer Alzheimer’s treatment may be on the horizon — but families still have meaningful choices today.
Many diagnosed patients won’t qualify — here are the
7 medical criteria.
New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.
In a one-hour seminar, a leading neurologist answers the most important questions families ask about what these new therapies can realistically deliver — from effectiveness and safety to eligibility, infusion logistics, cost, and access.
New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.
Poor sleep aggravates dementia and increases Alzheimer’s risk. Sleeping well restores and refreshes the brain. Learn to get a good night’s sleep to prevent and treat dementia. Check out these tips.
See why Leqembi is even more effective in males than females, at fighting Alzheimer’s.
Healthy foods make a healthy brain. Healthy food NETWORKS (which are the foods you eat together), may offer an even bigger benefit.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
